Share ownership Abbisko Cayman Limited

2256

KYG0028A1085

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 08:08:19 06/03/2026 GMT			5-day change	1st Jan Change
11.88 ^HKD	+4.76%		-6.53%	-8.69%

03-04	Abbisko Doses First Patient in Tumor Drug Trial	MT
03-03	Abbisko Cayman says CEO purchased total 45,000 shares of co at average price HK$11.26 per share	RE

Share class: Abbisko Cayman Limited

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	679,605,350	539,766,406 ( 79.42 %)	0	79.42 %

Major shareholders: Abbisko Cayman Limited

Name	Equities	%	Valuation
Yao Chang Xu 11.77 %	80,034,980	11.77 %	128 M $
LAV Management Co., Ltd. 6.015 %	40,905,790	6.015 %	65 M $
Qiming Venture Partners Ltd. 5.996 %	40,778,906	5.996 %	65 M $
Allianz Global Investors Asia Pacific Ltd. 5.77 %	39,241,000	5.77 %	63 M $
Futu Trustee Ltd. 4.52 %	30,738,202	4.52 %	49 M $
Zhui Chen 2.53 %	17,207,394	2.53 %	28 M $
Hong Ping Yu 2.528 %	17,190,394	2.528 %	28 M $
Fidelity Management & Research (Hong Kong) Ltd. 1.248 %	8,487,000	1.248 %	14 M $
Value Partners Ltd. 0.6484 %	4,410,000	0.6484 %	7 M $
OrbiMed Advisors Private Equity 0.6445 %	4,383,300	0.6445 %	7 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	21.35%
Individuals	17.21%
Other	4.52%
Unknown	56.92%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals	17.21%
China	12.53%
Hong Kong	12.35%
United States	0.98%

Based on 1000 largest holdings

Abbisko Cayman Ltd is a China-based clinical-stage biopharmaceutical company. The Company is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The Company owns two Core Product Candidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). ABSK091 is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. The Companyâ€™s products are primarily being developed for hepatocellular carcinoma (HCC), urothelial cancer (UC) and gastric cancer (GC).

Employees

226

Sector

Biotechnology & Medical Research

More about the company